Portrait of Michael Nauck – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Health > News > News 2016 > Honorary Doctors

17 November 2016

Portrait of Michael Nauck

Honorary Doctors

Since 1985, Professor Michael A. Nauck has had a close working relationship with SUND. As part of his work, he has contributed to a number of important and innovative findings within research into incretin, and for a number of years collaborated closely with Professor Jens Juul Holst and Associate Professor Carolyn F. Deacon, researchers at the Department of Biomedical Sciences. He is now being made an honorary doctor at the University of Copenhagen.

The highest level of academic recognition without the recipient defending a Danish doctoral dissertation – the German professor Michael A. Nauck can now add the title of honorary doctor at the University of Copenhagen to his CV. 

Professor Michael Nauck was the first researcher who recognised the potential of the hormone GLP-1 for treating patients with type 2 diabetes. The hormone was discovered by Professor Jens Juul Holst in 1987, and the discovery was quickly followed up by clinical studies that were headed by Michael Nauck. A ground-breaking study, which was published in 1993, showed for the first time the potential of the new hormone for treating type 2 diabetes. Later, this led to the development of incretin-based treatment, for which Michael Nauck is largely responsible. Through collaborating with Carolyn Deacon and Professor Jens Juul Holst, the proteolytic degradation of GLP-1 with the DPP-4 enzyme was demonstrated for the first time in humans, which led to the development of ​DPP 4-inhibitors which are now used all over the world.

“Michael Nauck has played an important role in the research into incretin. We have had a very good and constructive cooperation, which has resulted in many important findings which have been key to the modern treatment of type 2 diabetes. I hope that the new title will encourage him to visit Copenhagen even more often, so he has the opportunity to share his knowledge with colleagues and students alike,” says Professor Jens Juul Holst.

Michael Nauck’s long-standing cooperation with the University of Copenhagen has, in addition to being an academic success, also been very productive. Together with Carolyn Deacon and Jens Juul Holst, he has authored or co-authored 56 studies, and the research groups have a number of scientific articles in the pipeline at the moment. Together with his colleague, Professor Juris Meier, Michael Nauck has recently entered into a research alliance with the translational part of the Novo Nordisk Foundation Center for Basic Metabolic Research and has been awarded considerable funding.

Michael Nauck has had a leading position within the field of diabetes research in Germany for many years, and is also active at a senior level in various German diabetes patient associations. During his career, he has received a number of prestigious awards, and his studies have often been cited up to several hundred times. Currently, he is also acting head of clinical research at St. Josef-Hospital at Ruhr-University Bochum. In addition, he is a lecturer at the Medical Center at the University of Göttingen.